Cathepsin D and chromogranin A as predictors of long term disease specific survival after radical prostatectomy for localized carcinoma of the prostate - PubMed (original) (raw)
. 1997 Dec 1;80(11):2109-19.
Affiliations
- PMID: 9392333
Cathepsin D and chromogranin A as predictors of long term disease specific survival after radical prostatectomy for localized carcinoma of the prostate
D Theodorescu et al. Cancer. 1997.
Abstract
Background: The accumulation of chromogranin A (Chr A) and cathepsin D (Cath D) gene products may be important in prostate carcinoma progression. This study assessed whether the levels of immunoreactivity for Chr A and Cath D are better predictors of disease specific survival than conventional pathologic parameters of the primary tumor such as Gleason score, capsular penetration, seminal vesicle invasion, and percent tumor in the specimen for patients with clinically localized prostate carcinoma managed by radical prostatectomy.
Methods: Seventy-one patients with modified Jewett clinical stages A1 to B2 adenocarcinoma of the prostate underwent a radical prostatectomy after a negative metastatic workup. No neoadjuvant or adjuvant treatments were given and all disease recurrences and causes of death were recorded. Analysis of prostatectomy specimens was undertaken to determine the conventional pathologic parameters of the primary tumor and Chr A and Cath D immunohistochemical staining. Univariate and multivariate analyses were performed to determine the independent contributions of Chr A and Cath D in predicting survival.
Results: On univariate analysis Chr A was the only variable that reached statistical significance for disease specific survival (P = 0.035). Cath D nearly reached significance with a P value of 0.079 for disease specific survival. On multivariate analysis, the only independent factor predicting disease specific survival was the Chr A staining score (P < 0.05). In patients with unequivocal foci of Chr A immunoreactivity, the 14-year disease specific survival was 50% compared with 68% for patients lacking such foci.
Conclusions: The level of Chr A immunohistochemical staining is a strong predictor of disease specific survival and is superior to standard pathologic prognostic factors. Such findings lay the groundwork for future prospective study of the utility of such markers on biopsy specimens to predict patient outcome.
Similar articles
- p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate.
Theodorescu D, Broder SR, Boyd JC, Mills SE, Frierson HF Jr. Theodorescu D, et al. J Urol. 1997 Jul;158(1):131-7. doi: 10.1097/00005392-199707000-00040. J Urol. 1997. PMID: 9186339 - Predictors of Gleason pattern 4/5 prostate cancer on prostatectomy specimens: can high grade tumor be predicted preoperatively?
Rubin MA, Mucci NR, Manley S, Sanda M, Cushenberry E, Strawderman M, Montie JE, Bassily NH. Rubin MA, et al. J Urol. 2001 Jan;165(1):114-8. doi: 10.1097/00005392-200101000-00029. J Urol. 2001. PMID: 11125378 - Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy.
Blute ML, Bergstralh EJ, Iocca A, Scherer B, Zincke H. Blute ML, et al. J Urol. 2001 Jan;165(1):119-25. doi: 10.1097/00005392-200101000-00030. J Urol. 2001. PMID: 11125379 - Radical prostatectomy for pathological Gleason 8 or greater prostate cancer: influence of concomitant pathological variables.
Lau WK, Bergstralh EJ, Blute ML, Slezak JM, Zincke H. Lau WK, et al. J Urol. 2002 Jan;167(1):117-22. J Urol. 2002. PMID: 11743287
Cited by
- Evaluation of Gas 6 as a Prognostic Marker in Papillary Renal Cell Carcinoma.
Mikuteit M, Zschäbitz S, Stöhr C, Herrmann E, Polifka I, Agaimy A, Trojan L, Ströbel P, Becker F, Wülfing C, Barth P, Stöckle M, Staehler M, Stief C, Haferkamp A, Hohenfellner M, Duensing S, Macher-Göppinger S, Wullich B, Noldus J, Brenner W, Roos F, Walter B, Otto W, Burger M, Erlmeier M, Schrader AJ, Hartmann A, Erlmeier F, Steffens S; German Network Of Kidney Cancer. Mikuteit M, et al. Urol Int. 2023;107(7):713-722. doi: 10.1159/000529898. Epub 2023 Jun 22. Urol Int. 2023. PMID: 37348477 Free PMC article. - Expression of nectin-4 in papillary renal cell carcinoma.
Zschäbitz S, Mikuteit M, Stöhr C, Herrmann E, Polifka I, Agaimy A, Trojan L, Ströbel P, Becker F, Wülfing C, Barth P, Stöckle M, Staehler M, Stief C, Haferkamp A, Hohenfellner M, Duensing S, Macher-Göppinger S, Wullich B, Noldus J, Brenner W, Roos FC, Walter B, Otto W, Burger M, Schrader AJ, Hartmann A, Erlmeier F, Steffens S. Zschäbitz S, et al. Discov Oncol. 2022 Sep 22;13(1):90. doi: 10.1007/s12672-022-00558-2. Discov Oncol. 2022. PMID: 36136143 Free PMC article. - Growth Arrest-Specific 6 in Chromophobe Renal Cell Carcinoma.
Mikuteit M, Zschäbitz S, Erlmeier M, Autenrieth M, Weichert W, Hartmann A, Steffens S, Erlmeier F. Mikuteit M, et al. Oncology. 2022;100(10):536-541. doi: 10.1159/000525601. Epub 2022 Jun 27. Oncology. 2022. PMID: 35760058 Free PMC article. - Neuroendocrine differentiation in usual-type prostatic adenocarcinoma: Molecular characterization and clinical significance.
Kaur H, Samarska I, Lu J, Faisal F, Maughan BL, Murali S, Asrani K, Alshalalfa M, Antonarakis ES, Epstein JI, Joshu CE, Schaeffer EM, Mosquera JM, Lotan TL. Kaur H, et al. Prostate. 2020 Sep;80(12):1012-1023. doi: 10.1002/pros.24035. Epub 2020 Jul 10. Prostate. 2020. PMID: 32649013 Free PMC article. - Focal Neuroendocrine Differentiation of Conventional Prostate Adenocarcinoma as a Prognostic Factor after Radical Prostatectomy: A Systematic Review and Meta-Analysis.
Kardoust Parizi M, Iwata T, Kimura S, Janisch F, Abufaraj M, Karakiewicz PI, Enikeev D, Rapoport LM, Hutterer G, Shariat SF. Kardoust Parizi M, et al. Int J Mol Sci. 2019 Mar 19;20(6):1374. doi: 10.3390/ijms20061374. Int J Mol Sci. 2019. PMID: 30893781 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials
Miscellaneous